Newamsterdam Pharma
Clinical trials sponsored by Newamsterdam Pharma, explained in plain language.
-
New drug combo targets hidden heart risk in 16-Week trial
Disease control Recruiting nowThis study tests whether a new drug (obicetrapib) taken alone or with an existing medication (evolocumab) can lower lipoprotein(a) — a genetic risk factor for heart disease — in people with mild cholesterol problems. About 69 adults with elevated Lp(a) will take obicetrapib daily…
Phase: PHASE2 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated May 02, 2026 02:30 UTC
-
Healthy volunteers sought to test if experimental drug boosts antioxidant absorption.
Knowledge-focused Recruiting nowThis study tests whether the experimental drug obicetrapib can increase antioxidant levels in the blood and eyes of healthy people. One hundred volunteers will take either the drug or a placebo daily for four months. Researchers will measure antioxidant changes in blood and eye t…
Phase: PHASE2 • Sponsor: NewAmsterdam Pharma • Aim: Knowledge-focused
Last updated May 02, 2026 02:28 UTC